FDA Grants Breakthrough Therapy Designation to Innate Pharma’s Lacutamab for Sézary Syndrome
Innate Pharma SA announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing…
Read More...
Read More...
